Direct targeted therapy for MLL‐fusion‐driven high‐risk acute leukaemias

BACKGROUND: Improving the poor prognosis of infant leukaemias remains an unmet clinical need. This disease is a prototypical fusion oncoprotein‐driven paediatric cancer, with MLL (KMT2A)‐fusions present in most cases. Direct targeting of these driving oncoproteins represents a unique therapeutic opp...

Descripción completa

Detalles Bibliográficos
Autores principales: Cantilena, Sandra, Gasparoli, Luca, Pal, Deepali, Heidenreich, Olaf, Klusmann, Jan‐Henning, Martens, Joost H. A., Faille, Alexandre, Warren, Alan J., Karsa, Mawar, Pandher, Ruby, Somers, Klaartje, Williams, Owen, de Boer, Jasper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214753/
https://www.ncbi.nlm.nih.gov/pubmed/35730653
http://dx.doi.org/10.1002/ctm2.933

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214753/
https://www.ncbi.nlm.nih.gov/pubmed/35730653
http://dx.doi.org/10.1002/ctm2.933

Ejemplares similares